The introduction of the R21/Matrix-M malaria vaccine in Nigeria marks a historic milestone in the global fight against malaria. Since the program’s launch in December 2024, Nigeria has vaccinated over 58,000 children across two pilot states, achieving 25% of its annual target (WHO, 2024). Early data indicates promising results, with minimal vaccine wastage and no severe adverse effects reported (NPHCDA, 2025). While the program demonstrates significant potential in reducing Nigeria’s 26% share of the global malaria burden, key challenges in supply chain management, data tracking, and long-term financing must be addressed as the country prepares for nationwide expansion…Read more